Client & Alumni News

Cernostics’ TissueCypher® Identifies Patients with High-Risk for Esophageal Cancer

A newly released study indicates that Cernostics’ TissueCypher® identifies Barrett’s Esophagus patients who are 46x more likely to develop esophageal cancer or high-grade dyplasia as compared with low-risk patients. The test is 3x more effective than current pathological practices. Esophageal cancer is the fastest-growing cancer by incidence in western countries and early discovery dramatically improves the effectiveness of treatment. Read more: